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A thorough understanding of how proteins induce nanoparticle (NP) aggregation
is crucial when designing in vitro and in vivo assays and interpreting experimental
results. This knowledge is also crucial when developing nano-applications and 
formulation for drug delivery systems. In this study, we found that extraction of
immunoglobulin G (IgG) from cow serum results in lower polystyrene NPs
aggregation. Moreover, addition of isolated IgG or fibrinogen to fetal cow serum
enhanced this aggregation, thus demonstrating that these factors are major drivers
of NP aggregation in serum. Counter-intuitively, NP aggregation was inversely 
dependent on protein concentration; i.e., low protein concentrations induced 
large aggregates, whereas high protein concentrations induced small aggregates.
Protein-induced NP aggregation and aggregate size were monitored by absorbance
at 400 nm and dynamic light scattering, respectively. Here, we propose a mechanism
behind the protein concentration dependent aggregation; this mechanism involves
the effects of multiple protein interactions on the NP surface, surface area




Many nanoparticles have the tendency to aggregate 
in physiologically relevant buffers. This becomes a 
fundamental problem hindering systematic and repro-
ducible studies of the characteristics and effects of 
nanoparticles. In physiological environments, there are 
usually large varieties of proteins in high concentrations,  
which can either stabilize nanoparticle (NP) dispersion 
or induce aggregation. Therefore, adding proteins to 
experimental systems can further complicate these 
studies. Thus, a thorough understanding of how pro-
teins influence nanoparticles is necessary for evaluation 
of their effects regarding nanosafety and nanotoxicology 
and in the development of nano-applications for use 
in physiological environments. 
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In a complex biological environment (e.g., human 
blood, lung fluid, or cell medium), proteins will—in 
competition with each other—bind to the NP surface, 
forming a protein corona [1–9]. The protein corona 
changes over time [2, 4, 10, 11] depending on the 
surrounding protein concentration [3, 12] and their 
affinities for the NP surface. The fate depends both on 
the size, charge and material of the NPs and which 
protein it interacts with; thus, isolated proteins may 
or may not induce NP aggregation.  
No aggregation has been detected in previous 
studies using silica NPs mixed with human carbonic 
anhydrase, cytochrome C, or ribonuclease A [13–15]. 
The same trend has been observed for transferrin or 
serum albumin mixed with sulfonated polystyrene 
NPs [16, 17], while other studies show that gold NPs 
are stabilized by serum albumin and cytochrome C 
[18–21]. Lysozyme, however, can induce the strong 
aggregation of silica, polystyrene, and gold NPs 
[17, 22–25], which also is observed when fibrinogen 
is incubated with polystyrene and silica NPs [26]. 
Interestingly, fibrinogen induces aggregation of poly- 
(acrylic acid)-conjugated gold NPs [27] in a protein 
concentration-dependent manner. Titanium dioxide 
NPs can form large micrometer-sized aggregates in 
many protein-containing fluids [1], while other metal 
oxides—Fe2O3, ZnO, and surface functionalized Fe3O4, 
for example—are instead stabilized by serum proteins 
[28–30]. Polystyrene NPs in blood plasma induce large, 
nanometer-sized complexes, probably consisting of 
proteins and multiple particles [3, 12]. Gold NPs induce 
large, nano-sized aggregates without indication of 
particle agglomeration [2, 5], implying that proteins 
can serve as a link between particles. The aggregation 
of NPs in blood plasma or serum also depends on 
particle size, protein concentration, incubation time, 
and buffer composition [3, 5, 8, 9, 11, 12, 31, 32]. 
Immunoglobulin G (IgG)—the second most abundant 
protein in human blood plasma and extracellular 
fluid—is an antibody isotype vital for immune system 
function. Here, it binds pathogens resulting in their 
immobilization and agglutination, coats the pathogen 
surfaces (opsonization) allowing their recognition 
and phagocytosis, activates the classical pathway of 
the complement system, and binds and neutralizes 
toxins. Despite its role in the immune system and 
importance in many medical applications, IgG is rarely 
used as a model protein in protein-NP interactions. 
Knowledge of how different proteins affect NP 
aggregation is important when designing and inter-
preting any experiment that involves both proteins 
and nanoparticles, for example, protein binding, in 
vitro and in vivo assays, and formulation of medical 
delivery systems. 
In this study, we investigated protein-induced  
NP aggregation and found that IgG induces NP 
aggregation in a counter-intuitive concentration- 
dependent manner and also drives NP aggregation in 
blood serum. This process is dependent on the NP 
material, the protein, and the environment. 
2 Experimental 
2.1 NPs and proteins 
Polystyrene (PS) and polymethyl methacrylate (PMMA) 
NPs were purchased from Bangs Laboratories, Inc. 
(Fisher, IN, USA). Two PS NPs with different surface 
modifications were used: sulfonated (PS-OSO3H) and 
carboxylated (PS-COOH). The mean hydrodynamic 
diameter—measured by dynamic light scattering (DLS) 
using a Malvern Zeta NANO ZS (Malvern Instrument 
Limited, Malvern, UK) for PS-OSO3H and PS-COOH 
NPs is 27 nm (Table S1 and S2 in the Electronic 
Supplementary Material (ESM)). PS-OSO3H and PS- 
COOH NPs have a Zeta potential of around –45 mV 
[33]. Mannan nanogel was synthesized as previously 
described [34] with near neutral charge and mean 
hydrodynamic diameter of 154 nm. Human IgG was 
purchased from Lee Biosolutions (St. Louis, MO, USA). 
Fc and Fab fragments from human IgG were purchased 
from Meridian Life Science, Inc. (Memphis, TN, USA). 
Human fibrinogen and fatty acid free human serum 
albumin (HSA; A3782) were purchased from Sigma- 
Aldrich (St. Louis, MO, USA). The HSA monomer was 
purified from dimers and oligomers as previously 
described [17]. Different qualities of fibrinogen, with 
respect to purity, were tested and differing results 
were obtained for these: F4883: 35%–65% protein, 
≥90% which is clottable; or F3879: 50%–70% protein, 
≥80% of protein is clottable. Both were purchased 
from Sigma-Aldrich. The presented data is from   
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the highest quality tested (F4883). Cow serum was 
purchased from Innovative Research (Novi, MI, USA). 
All dilutions of NPs, proteins, and serum were made 
in PBS (pH 7.5; 10.1 mM Na2HPO4, 137 mM NaCl, 
2.7 mM KCl, 1.8 mM KH2PO4). 
2.2 IgG purification 
Bovine IgG was purified from cow serum, (Innovative 
research, IBV-SER) using affinity chromatography on 
Pierce Protein A/G Plus Agarose column (Fisher 
Scientific AB, 20423; Fisher Scientific AB, Waltham, 
MA, USA). The cow serum was filtered through a 
1.2-μm filter before it was added to the PBS-washed 
column (Fig. S1, step 1, in the ESM) and incubated at 
room temperature for 25–30 min (Fig. S1, step 2, in the 
ESM). Thereafter, the cow serum was collected (same 
volume as was applied to the column) and non-IgG 
material was washed with PBS until A280 was close to 
zero (Fig. S1, step 3, in the ESM). Then, 0.1 M glycine 
pH 2.5 was applied to dissociate the Protein A/G–IgG 
interaction and the eluate was collected into tubes 
containing 1 M Tris-HCl pH 8.8 (120 μL/1 mL fraction) 
(Fig. S1, step 4, in the ESM). The tubes were monitored 
at A280 and the fractions containing IgG with highest 
absorbance was pooled and dialyzed against PBS 
(Fig. S2(a) in the ESM). The cow serum eluted after 
incubation was applied to the column for a second time 
and the same purification procedure was repeated 
(Fig. S1, step 1–4, in the ESM). SDS-PAGE was used 
to characterize the cow serum before and after IgG 
was removed and also to assess the IgG purity. The 
samples were incubated and heated at 95 °C with 
mercaptoethanol before loading on the gel (Fig. S2(b) 
in the ESM).  
2.3 Aggregation measured by UV spectroscopy 
NP aggregation was monitored by measuring absor-
bance at 400 nm on an UV-1800 UV spectrometer 
(Shimadzu, Japan). At this wavelength, the turbidity 
of the sample is measured (i.e. how much light is 
scattered by particles in the solution). At the con-
centrations used, neither NPs nor proteins absorbed 
significantly at 400 nm. However, some absorbance 
was recorded at high protein concentrations. This value 
was subtracted from that of the formed aggregates. 
Before measurements were taken, 150 μL of NPs 
PS-OSO3H, PS-COOH, PMMA, or mannan nanogel 
at a concentration of 1 or 0.5 mg/mL were mixed with 
1.35 mL IgG, HSA, a mixture of HSA/IgG, IgG Fc 
fragments, IgG Fab fragments, fibrinogen, or lysozyme. 
The protein concentrations varied between 0.005 and 
5 mg/mL, as indicated in the tables and figures. 
Aggregation in cow serum or fetal calf serum (FCS) 
was achieved by mixing serum dilutions with PS- 
OSO3H. In some experiments, IgG was added to the 
FCS before adding NPs. The final concentration of 
serum, added IgG, and NPs are indicated in the text 
and figure labels. The mixtures were incubated for  
at least 1 h before the absorbance was monitored at 
400 nm. The experiments were performed in at least 
triplicates. The same conditions were used for kinetics 
experiments, but the absorbance at 400 nm was 
measured immediately, with a lag time of 5 to 10 s, and 
then every 5 s for 10 to 20 min. The time at which half 
of the aggregation was completed, as measured by the 









           (1) 
where Abs is the absorbance at 400 nm, Abs0 is the 
absorbance at 400 nm at time zero, Absmax is the 
absorbance at 400 nm when the steady state is reached, 
t is the time in seconds, and t1/2 is the time in seconds 
when half of the reaction is completed. 
2.4 Size of the aggregates measured with DLS 
The hydrodynamic diameter of NPs and protein/NP 
mixtures was determined by DLS using a Malvern 
Zeta NANO ZS. The reported hydrodynamic diameter 
results from size distribution analysis. Before measure-
ments were taken, human IgG, HSA, a mixture of 
HSA/IgG, or human fibrinogen in PBS were incubated 
with 27 nm PS-OSO3H or PS-COOH NPs in PBS for  
at least 1 h at 23 °C. The final NPs concentration was 
0.05 mg/mL. Protein concentration varied from 0.005 
to 3 mg/mL, as indicated in tables and figures. The 
results are presented as the mean of at least three 
measurements. To evaluate the influence of different 
buffers on the NP size, DLS measurements were 
performed in PBS and 10 mM HEPES buffer, 150 mM 
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NaCl, pH 7.4. The NP size was the same in both buffers 
(data not shown). 
2.5 Circular dichroism (CD) spectroscopy and 
intrinsic tryptophan fluorescence spectroscopy 
Different concentrations of PS-OSO3H, PS-COOH, or 
mannan nanogel diluted in PBS with 0.1 mM EDTA 
were mixed with proteins dissolved in the same 
solution. NPs were added to the protein solution and 
incubated for 30 ± 5 min before recording spectra. 
The CD signal was recorded between 260 and 200 nm 
in a quartz (QS) cuvette with 1 mm path length at 37 °C 
using a Jasco J-815 CD spectrometer (Jasco Analytical 
Instruments, Easton, MD, USA). The scanning rate 
was 50 nm/min, the digital integration time per data 
point (DIT) was 8 s, and the data collected were from 
an average of five accumulations.  
The fluorescence emission spectrum was recorded at 
37 °C in 10 or 3 mm QS cuvettes using a Perkin-Elmer 
LS 50 B luminescence spectrometer (Perkin-Elmer, 
Waltham, MA, USA) between 310 and 420 nm after 
excitation at 290 nm at a scan rate of 50 nm/min. The 
excitation and emission slits were set to 3 nm. The 
data collected was from an average of three accu-
mulations and the background signal from the NPs 
was subtracted from the overall read. Samples were 
handled in the same way as in the CD spectroscopy 
experiments. 
Identical NPs titrations into protein-free buffer, 
PBS with 0.1 mM EDTA were performed, and the CD 
and fluorescence signals were recorded. In the case  
of fluorescence, these data were used for baseline 
subtraction from the protein-NPs data. Typically, the 
CD signal-to-noise ratio was higher in the presence 
than in the absence of proteins. Therefore, the CD 
results are reported without subtracting the background 
signal. 
2.6 Light microscopy 
Aggregates were imaged in a clear 96-well plate 
(Nunc, Rochester, NY, USA) using an Olympus IX71 
microscope (Olympus, Tokyo, Japan). Images were 
acquired using Olympus cellSens digital imaging 
software. 
3 Results and discussion 
To investigate if IgG was responsible for inducing 
NP aggregation in blood serum, PS-OSO3H NPs were 
incubated in FCS, cow serum, or cow serum depleted 
of bovine IgG by affinity chromatography (Fig. S1 in 
the ESM). If IgG is responsible for NP aggregation, less 
aggregation would be expected in FCS as compared 
to that for cow serum and cow serum without IgG. 
FCS was selected because the biological impact of NPs 
is often evaluated by studying human cell cultures 
with FCS in the growth medium. Indeed, strong 
aggregation was seen in diluted cow serum, with less 
aggregation observed in IgG-depleted cow serum as 
monitored by measuring the absorbance at 400 nm 
(Fig. 1(a)). Strikingly, no aggregation was seen in FCS, 
regardless the serum concentration (Fig. 1(a)). This 
demonstrated that NP aggregation in cow serum 
decreased as the serum concentration increased, 
indicating that other proteins or biomolecules might 
inhibit NP aggregation in high serum concentrations. 
Thus, many problems experienced in cell experiments 
performed at low serum concentrations may be absent 
in full blood. Increasing the NPs concentration in 1% 
serum revealed that the aggregation is clearly par-
ticle concentration-dependent (Fig. 1(b)). Cow serum 
induced highest NP aggregation at all concentrations, 
and FCS lowest, whereas IgG-depleted cow serum 
yielded an intermediate aggregation. Adding isolated 
bovine IgG to FCS and IgG-depleted cow serum 
restored this aggregation (Fig. 1(c)). These results 
strongly indicate that IgG is an important factor 
driving PS-OSO3H aggregation in serum. Therefore, 
NP aggregation with isolated bovine IgG was inves-
tigated. As shown in Fig. 1(d), NP aggregation is 
dependent on the protein concentration. Samples at 
different IgG:NP ratios were also imaged with light 
microscopy (Fig. S3 in the ESM). At low absorbance 
(NP only, few or many IgG/NP) no or few small visible 
aggregates were observed (Figs. S3(a)–S3(c) and S3(f) 
in the ESM), whereas visible aggregates become more 
pronounced at higher absorbance (Figs. S3(d) and 
S3(e) in the ESM). This corresponds to the absorbance 
profiles at 400 nm (Fig. 1(d)). 
Next, we investigated IgG-driven NP aggregation 
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in detail in PBS. Human IgG is used for the following 
experiments. In addition to PS-OSO3H, we also used 
PS-COOH NPs, which have different surface groups 
but both are negatively charged at pH 7.5. PS-OSO3H 
or PS-COOH NPs were mixed with increasing con-
centrations of IgG (Fig. 2). The absorbance increases 
at around 5 to 10 IgG molecules per NP, indicative  
of aggregate formation (Figs. 2(a) and 2(b)). Further 
increases in the number of IgG molecules failed to 
elicit any significant differences in absorbance until a 
minimum of 40 to 100 molecules was reached. Above 
100 IgG molecules per NP, the absorbance decreases 
and the solutions become transparent, indicating that 
no or small aggregates formed. These results reveal 
an inverse correlation between the number of IgG 
molecules in the solution and the degree of aggregation, 
which is similar to the aggregation behavior observed 
with isolated bovine IgG (Fig. 1(d)). Increasing the 
particle concentration two-fold resulted in a similar 
aggregation profile (Figs. 2(a) and 2(b)). To investigate 
if the structural change of IgG was causing the NP 
aggregation, the secondary and tertiary structure 
were monitored with CD and intrinsic tryptophan 
fluorescence spectroscopy, respectively. Changes in 
the tertiary structure were observed, seen as a decrease 
in intensity, but no shift in the tryptophan emission 
was detected. The secondary structure, however, was 
slightly affected when IgG bound to the NPs (Fig. S4 
in the ESM). This data implies that IgG denaturation 
was not required for the aggregation to occur.  
To determine the size of the PS-OSO3H:IgG com-
plexes, DLS was studied at various IgG concentrations 
(Fig. 2(c) and Table S1 in the ESM). At 2.8 IgG 
molecules per NP, the hydrodynamic diameter of the 
PS-OSO3H:IgG complexes was approximately 50 nm, 
indicating formation of small aggregates. At 28 IgG 
molecules per NP, the diameter reached over 2,000 nm, 
denoting large aggregates of multiple NPs and IgG 
 
Figure 1 (a) PS-OSO3H was mixed with increasing concentrations of cow serum (red), IgG-depleted cow serum (green), or FCS 
(blue) and the absorbance at 400 nm was measured. The final NP concentration was 50 µg/mL. (b) 1% cow serum (red), IgG-depleted 
cow serum (green), or FCS (blue) were mixed with increasing concentrations of PS-OSO3H. (c) IgG-depleted cow serum (green) or FCS 
(blue) was complemented with isolated bovine IgG before PS-OSO3H was added. The final NP concentration was 60 µg/mL. (d) PS-OSO3H 
was mixed with increasing concentrations of isolated bovine IgG. The final NP concentration was 50 µg/mL. All samples were incubated
for at least 1 h before the measurement. The reported value is the mean ± S.D. of at least 3 experiments. 
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molecules. At 112 IgG molecules per NP, the diameter 
is 128 nm and the highest absorbance was observed. 
This discrepancy between absorbance and DLS data 
can likely be explained by a large number of 
aggregates. The correlation between the observed 
absorbance and the increase in aggregation is not 
straightforward. Aggregates will scatter light resulting 
in an increase in the apparent absorbance, which 
increases exponentially with aggregate size. Therefore, 
an increase in the number of aggregates or in the size 
of aggregates will change the observed absorbance 
differently. At 560 IgG molecules per NP, two peaks 
corresponding to 15 and 70 nm in diameter, where 
the smaller probably represents unbound IgG. DLS 
data (Fig. 2(d) and Table S2 in the ESM) of PS-COOH 
confirms that this IgG-driven aggregation is similar 
to the one observed with PS-OSO3H NPs.  
A possible explanation behind the IgG-induced 
aggregation is that IgG acts or serves as a protein 
bridge between NPs to form large aggregates. However, 
bridging can only occur if there is more than one 
surface to which IgG can bind. Limited digestion   
of IgG by papain produces Fc and Fab fragments 
(Scheme 1). Adding PS-OSO3H or PS-COOH NPs to Fc 
induced minor changes in the CD spectra, while Fab 
slightly affected the intrinsic tryptophan fluorescence 
spectra (Figs. S5 and S6 in the ESM). This indicates 
that both Fc and Fab interact with the NPs. Furthermore, 
addition of Fc to PS-COOH induced concentration- 
dependent NP aggregation, similar to what is observed 
with IgG, indicating that Fc interacts with the NPs 
with at least two binding sites. In contrast, the 
addition of Fab fragments failed to induce PS-COOH  
 
Scheme 1 Fc and Fab fragments obtained after cleavage of IgG 
with papain. 
 
Figure 2 PS-OSO3H (a) or PS-COOH (b) NPs were mixed with different IgG concentrations and incubated for at least 1 h before the 
absorbance at 400 nm was measured. The final NP concentration was 0.05 mg/mL (open circles) or 0.1 mg/mL (closed circles) and the 
IgG concentration varied between 0.001 and 3 mg/mL. DLS measurements for some selected IgG concentrations mixed with 0.1 mg/mL 
(c) PS-OSO3H or (d) PS-COOH NPs. The digits 0, 2.8, 28, 112, and 560 indicate the number of IgG molecules per NP. The reported
value is the mean ± S.D. of 3 to 9 experiments. 
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NP aggregation (Fig. S7 in the ESM). A large excess of 
Fab could likely induce a small amount of aggregation, 
probably due to Fc impurities in the Fab preparation 
(data not shown). This implies that the NP aggregation 
is not driven by major structural changes. 
PMMA NPs likewise aggregate with increasing 
concentrations of IgG (Fig. S8 in the ESM). Interestingly, 
the aggregation profile is similar to those obtained 
with PS-OSO3H and PS-COOH. In contrast, IgG failed 
to induce the aggregation of mannan nanogel (data 
not shown). However, the changes in CD and mainly 
in the intrinsic tryptophan fluorescence spectra of 
IgG after the addition of mannan nanogel strongly 
indicated that IgG bound to the nanogel (Fig. S9 in 
the ESM), does not automatically result in particle 
aggregation. 
The NP aggregation induced by fibrinogen is, as for 
IgG, dependent on the protein concentration (Fig. 3(a)).  
 
Figure 3 Fibrinogen driven aggregation of 27 nm PS-OSO3H 
and PS-COOH NPs. (a) The final NP concentration was 0.1 mg/mL. 
The fibrinogen concentrations varied between 0.001 and 5 mg/mL. 
(b) PS-OSO3H NPs were mixed with different concentrations  
of FCS without (white bars) or with added human fibrinogen 
(0.083 mg/mL, grey bars). The samples were incubated for at 
least 1 h before aggregation was measured. The reported value is 
the mean ± S.D. of 3 experiments. 
In contrast to IgG, there are large structural changes 
in fibrinogen that occur after binding to the NPs 
(Fig. S10 in the ESM). DLS data show that the mean 
hydrodynamic diameter of the formed aggregates 
follows the same pattern as for IgG (Table S3 in the 
ESM). Large aggregates form at low fibrinogen con-
centrations but, at high fibrinogen concentrations, the 
size of the PS-OSO3H:fibrinogen complex is about 
75 nm. Adding fibrinogen to FCS also induces the 
strong aggregation of PS-OSO3H NPs (Fig. 3(b)). The 
fibrinogen concentration in serum is close to 3 mg/mL 
in plasma and uncoagulated blood; therefore, 
fibrinogen together with IgG is probably the primary 
driver of NP aggregation in blood. The same con-
centration dependent fibrinogen-induced aggregation 
in buffer was previously shown for polyacrylic acid- 
conjugated gold NPs [27]. The authors suggest that 
when there is an excess of particle surface, fibrinogen 
acts as a bridge between them to form large aggregates 
but, when there is an excess of fibrinogen, the NP 
surface is rapidly covered by protein to prevent 
bridging between the NPs. 
Our data on the IgG-driven aggregation of PS-OSO3H, 
PS-COOH, and PMMA NPs supports the proposed 
mechanism. We suggest that the important features 
of protein concentration-dependent aggregation can 
be described by considering four regimes (Scheme 2). 
In the first regime, there is a large excess of NPs 
resulting in a mixture of empty NPs, NPs with one 
IgG, and small aggregates where IgG functions as a 
bridge between two NPs. In the second regime, there 
are more IgG molecules per NP but still an excess of 
NP surface; therefore, one IgG molecule already 
bound to a NP can still bind to more than one NP 
and bridging can occur in many different directions 
to generate large aggregates. In the third, there is less 
available surface area and finding an empty area on a 
second NP for IgG to bind will take longer time, and 
therefore more smaller aggregates form. In the fourth 
regime, there is a large excess of IgG, leading to a 
decrease in aggregation because the NP surface becomes 
rapidly covered by IgG. Thus, at very high protein 
concentrations, no particle aggregation occurs since 
single particles are quickly covered by a protein 
monolayer. 
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Scheme 2 Aggregation of PS and PMMA NPs with increasing 
IgG concentration. Aggregates of different sizes are formed 
depending on the ratio of IgG and available surface area. 
The described mechanism can be validated with two 
predictions. First, reducing the available surface area 
should decrease the size of the aggregates. As shown 
above, the NP aggregation is lower in high concen-
trations of blood serum than that in low concentrations 
(Fig. 1). This indicates that there are substances in 
serum that inhibit NP aggregation, which implies 
that the first prediction is correct. Albumin is a likely 
candidate, as it is the most abundant protein in blood 
serum, binds to PS-OSO3H and PS-COOH [17], and 
cannot by itself induce particle aggregation (data not 
shown). Indeed, adding HSA to the PS-COOH NP 
before adding IgG reduces the NP absorbance (Fig. 4(a)) 
and the diameter of the formed aggregates (Fig. 4(b)) 
compared to that with IgG alone. Interestingly, the 
aggregation profile is still dependent on the IgG 
concentrations (Fig. 4(c)). The order of adding HSA 
and IgG to the NPs is important since adding the same 
amount of HSA to IgG prior to adding PS-COOH 
NPs to the protein mixture increases the absorbance 
compared to first adding HSA to the particles (Fig. 4(d)). 
This implies that the system is kinetically, rather than 
thermodynamically, driven over the time period of 
our experiments. Another way to reduce the surface 
area is to keep the added mass and increase the NP 
size. The addition of same amount of IgG to 60 nm 
PS-COOH NPs shifts the aggregation profile compared 
to 26 nm NPs (Fig. S11 in the ESM). As expected, less 
 
Figure 4 IgG-driven aggregation of PS-COOH NPs in the presence of HSA. (a) and (b) HSA was mixed with PS-COOH NPs before 
IgG was added and (a) the absorbance at 400 nm was measured or (b) the hydrodynamic diameter was measured by DLS. The final NP 
and IgG concentrations were 0.1 and 0.4 mg/mL, respectively. (c) IgG was mixed with PS-COOH NPs or NPs pre-incubated with HSA 
and the absorbance was measured. The IgG concentration ranged between 0.001 and 3 mg/mL and the final NP and HSA concentrations 
were 0.1 mg/mL, (d) NPs were mixed with a premix of IgG/HSA (white bar), premixed with HSA and then IgG (grey bar), or premixed
with IgG and then HSA (black bar). The reported value is the mean ± S.D. of 3 experiments. 
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amount of IgG is required to reduce the aggregation 
of the 60 nm NP (Fig. S11(a) in the ESM) as the total 
surface area is smaller. Furthermore, the number of 
IgG per NP needed to reduce the aggregation is higher 
since the surface area per NP is larger (Fig. S11(b) in 
the ESM). These experiments further strengthen the 
importance of the relationship between available 
surface area and the IgG-driven aggregation. 
The second prediction is that the kinetics of the 
formation of larger aggregates should become retarded 
with increasing IgG concentrations. To verify this, 
the aggregation kinetics of PS-OSO3H and PS-COOH 
NPs mixed with IgG were studied by following   
the absorbance over time at 400 nm. Note that the 
aggregation process is followed for 1,200 s compared 
to 1 h or more in the previous measurements, and is 
the main reason why the absorbance might differ at 
the same IgG:NP ratios between the experiments. 
The lag time between mixing and the first reading is 
about 5 s. Examples of interesting differences in 
kinetics are shown in Figs. 5(a) and 5(b). The time 
point at which half of the process in this time range is 
completed, t1/2, was extracted from Eq. (1) by fitting 
that function to the experimental data (Figs. 5(c) and 
5(d)). At IgG concentrations corresponding to 10 to 
50 IgG molecules per NP, the aggregation was fast. 
Adding more IgG decreases the aggregation rate 
indicating that the second prediction is correct, (i.e., 
the kinetics of the aggregate formation slows down as 
the available surface area becomes limited). However, 
at the highest IgG concentrations, the aggregation 
rate increases again probably because only small 
aggregates of one or few particles rapidly forms (see 
regime 4 in Scheme 2). Note that the low absorbance 
makes it difficult to estimate the t1/2 of aggregation at 
high IgG concentrations. 
In the last few years, attention has been drawn to 
the protein corona that forms around NPs. Studying 
the protein corona may seem to be a straightforward 
project. However, the aggregation profile of IgG and 
fibrinogen highlights the need for caution. When the 
NPs aggregate into large complexes in protein-rich 
fluid, there will be many protein bridges that form 
strongly associated aggregates. Other proteins with  
 
Figure 5 The aggregation kinetics of PS-OSO3H (a) and of PS-COOH (b) for some selected IgG concentrations. The digits 24, 30, 90, 
and 300 correspond to the number of IgG molecules per NP. The final concentration of NPs was 0.05 mg/mL. The half-time of 
aggregation for PS-OSO3H (c) and of PS-COOH (d) was calculated as described in material and methods. The final NP concentration 
was 0.05 mg/mL (open circles) or 0.1 mg/mL (closed circles) and the IgG concentration varied between 0.001 and 3 mg/mL. 
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no or weak affinity to the NPs may be trapped in  
the aggregates induced by IgG or other proteins. The 
bridging proteins and the trapped proteins may be 
interpreted as proteins with high affinity. Moreover, 
diluting the protein-rich fluids can alter how the 
proteins affect NP aggregation. Consequently, studies 
on any aspect of the protein corona at only one 
protein/NP ratio may not adequately describe the 
corona at physiologically relevant conditions. 
Monoclonal antibodies (mAb) are used as active 
compounds in many biopharmaceutical drugs and are 
formulated either as liquids or as lyophilized products. 
In recent years, there has been a considerable research 
interest in the area of drug delivery of mAbs using 
NPs. Formulating the mAb together with NPs may 
provide for drug delivery at a controlled and sustained 
rate and, consequently improve the pharmacokinetic 
and pharmacodynamic properties of the compound. 
A potential challenge with mAb/NP formulations is 
that the NPs may form particle-particle aggregates, 
and potentially NP-mAb aggregates. It is a regulatory 
demand to minimize aggregates in biopharmaceutical 
drug products since they may cause safety problems, 
such as immunogenicity. In this report, we have 
shown that concentration-dependent IgG/NP-induced 
aggregation may be counter-intuitive. Although only 
a few NPs were investigated here, it is not unlikely that 
a similar behavior is observed in biopharmaceutical 
mAb/NP systems also. If so, this finding may    
have implications for future mAb/NP formulation 
development. 
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